(6CI)-(3,5-二甲基-4-异噁唑)-脲 | 99979-64-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (6CI)-(3,5-二甲基-4-异噁唑)-脲
• 英文名称: (3,5-dimethyl-isoxazol-4-yl)-urea
• 英文别名: (3,5-Dimethyl-isoxazol-4-yl)-harnstoff；(3,5-Dimethyl-1,2-oxazol-4-yl)urea
• CAS: 99979-64-3
• 化学式: C₆H₉N₃O₂
• mdl: MFCD01313311
• 分子量: 155.156
• InChiKey: CSLRISDYBRAABM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  81.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  4-氨基-3,5-二甲基异恶唑 、 potassium cyanate 在 盐酸 作用下， 生成 (6CI)-(3,5-二甲基-4-异噁唑)-脲
  参考文献：
  名称：

  Musante; Stener, Gazzetta Chimica Italiana, 1959, vol. 89, p. 1579,1594

  摘要：

  DOI：

文献信息

• Substituted Imidazopyridinyl-Aminopyridine Compounds
  申请人：Ashwell Mark A.

  公开号：US20110172203A1

  公开（公告）日：2011-07-14

  The present invention relates to substituted imidazopyridinyl-aminopyridine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted imidazopyridinyl-aminopyridine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及取代咪唑吡啶基-氨基吡啶化合物及合成这些化合物的方法。本发明还涉及含有取代咪唑吡啶基-氨基吡啶化合物的药物组合物，以及通过向需要的受试者施用这些化合物和药物组合物来治疗细胞增殖性疾病，如癌症的方法。
• [EN] NOVEL FUSED PYRROLOCARBAZOLES<br/>[FR] NOUVEAUX PYRROLOCARBAZOLES FONDUS
  申请人：CEPHALON INC

  公开号：WO2005063763A1

  公开（公告）日：2005-07-14

  The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.

  本发明涉及选定的融合吡咯烷基咔唑，包括其医药组合物及用于治疗疾病的方法。本发明还涉及中间体和制备这些融合吡咯烷基咔唑的方法。
• Novel quinazoline derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20070010671A1

  公开（公告）日：2007-01-11

  The present invention relates to novel compounds of Formula (1): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(1)，并作为MCH受体拮抗剂。这些化合物在制药组合物中的使用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗塞、暴食障碍（包括贪食症、厌食症）、精神障碍（包括躁郁症、精神分裂症、谵妄、痴呆）、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍（包括帕金森病、癫痫和成瘾）。
• NOVEL FUSED PYRROLOCARBAZOLES
  申请人：CEPHALON, INC.

  公开号：EP1704148B1

  公开（公告）日：2011-03-02
• Novel Fused Pyrrolocarbazoles
  申请人：Becknell Nadine C.

  公开号：US20100152196A1

  公开（公告）日：2010-06-17

  The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.